SG10201803999UA - Recombinant factor viii formulations - Google Patents

Recombinant factor viii formulations

Info

Publication number
SG10201803999UA
SG10201803999UA SG10201803999UA SG10201803999UA SG10201803999UA SG 10201803999U A SG10201803999U A SG 10201803999UA SG 10201803999U A SG10201803999U A SG 10201803999UA SG 10201803999U A SG10201803999U A SG 10201803999UA SG 10201803999U A SG10201803999U A SG 10201803999UA
Authority
SG
Singapore
Prior art keywords
factor viii
recombinant factor
formulations
viii formulations
recombinant
Prior art date
Application number
SG10201803999UA
Inventor
De Qian Wang
Xinghang Ma
Nelly Tsvetkova
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SG10201803999UA publication Critical patent/SG10201803999UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Abstract

RECOMBINANT FACTOR VIII FORMULATIONS Provided are liquid and lyophilized recombinant Factor VIII formulations, including formulations for polymer-conjugated FVIII such as PEGylated Factor VIII. FIGURE 18
SG10201803999UA 2013-03-15 2014-03-11 Recombinant factor viii formulations SG10201803999UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15
US201361869191P 2013-08-23 2013-08-23

Publications (1)

Publication Number Publication Date
SG10201803999UA true SG10201803999UA (en) 2018-06-28

Family

ID=51580768

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201803999UA SG10201803999UA (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations
SG11201507618YA SG11201507618YA (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201507618YA SG11201507618YA (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Country Status (17)

Country Link
US (1) US20160030524A1 (en)
EP (1) EP2970430A4 (en)
JP (1) JP2016518321A (en)
KR (1) KR20150132449A (en)
CN (1) CN105209487A (en)
AU (1) AU2014237111B2 (en)
BR (1) BR112015022730A2 (en)
CA (1) CA2905739A1 (en)
HK (1) HK1213273A1 (en)
MX (1) MX2015012905A (en)
PE (1) PE20160121A1 (en)
RU (1) RU2015144076A (en)
SG (2) SG10201803999UA (en)
TW (1) TW201521761A (en)
UY (1) UY35412A (en)
WO (1) WO2014150477A1 (en)
ZA (1) ZA201507684B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3247400A1 (en) * 2015-01-18 2017-11-29 Biogen MA Inc. Formulations and screening of biological therapeutic agents
TWI777175B (en) 2015-11-13 2022-09-11 日商武田藥品工業股份有限公司 Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
TW202039546A (en) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
US20220305089A1 (en) * 2019-08-16 2022-09-29 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP1152450A4 (en) * 1999-02-01 2004-04-14 Nippon Electric Glass Co Cathode-ray tube and its production method
US6586573B1 (en) * 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
WO2002103024A2 (en) * 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
MX2007005466A (en) * 2004-11-12 2007-10-19 Bayer Healthcare Llc Site-directed modification of fviii.
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
ES2706296T3 (en) * 2008-11-07 2019-03-28 Univ Connecticut Formulations of Factor VIII
WO2010083536A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety

Also Published As

Publication number Publication date
EP2970430A1 (en) 2016-01-20
JP2016518321A (en) 2016-06-23
ZA201507684B (en) 2017-06-28
SG11201507618YA (en) 2015-10-29
KR20150132449A (en) 2015-11-25
MX2015012905A (en) 2016-06-16
WO2014150477A1 (en) 2014-09-25
AU2014237111A1 (en) 2015-10-08
BR112015022730A2 (en) 2017-10-31
EP2970430A4 (en) 2017-01-11
CA2905739A1 (en) 2014-09-25
PE20160121A1 (en) 2016-03-03
CN105209487A (en) 2015-12-30
HK1213273A1 (en) 2016-06-30
UY35412A (en) 2014-10-31
AU2014237111B2 (en) 2018-06-21
RU2015144076A (en) 2017-04-24
US20160030524A1 (en) 2016-02-04
TW201521761A (en) 2015-06-16

Similar Documents

Publication Publication Date Title
MY191035A (en) Affinity-oligonucleotide conjugates and uses thereof
MX2016007063A (en) Therapeutic peptides.
MX2021012014A (en) Adeno-associated virus factor viii vectors.
SG10201803042PA (en) Anti-tim-3 antibodies
IL238130B (en) Recombinant modified viruses comprising pr13.5 promoter and uses thereof
PH12015501392A1 (en) Pesticidal compositions and processes related thereto
MY181190A (en) Improved adenovirus formulations
EP3043820A4 (en) Methods and compositions comprising purified recombinant polypeptides
MX357202B (en) Virus like particle composition.
PH12015501394A1 (en) Pesticidal compositions and processes related thereto
CY1117214T1 (en) COMPOSITION FOR CONTROLLED OVENTION STUDY
SG11201505924TA (en) Factor viii polypeptide formulations
EP2981543A4 (en) Novel 4 7 peptide antagonists
SG10201803370XA (en) Conjugates of somatostatin and its analogs
WO2013123046A3 (en) Cathode buffer materials and related devices and methods
SG10201803999UA (en) Recombinant factor viii formulations
MX2015011052A (en) Oral care compositions.
EP3052526A4 (en) Recombinant polypeptides comprising mhc class ii 1 domains
PT2899198T (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use
MX349487B (en) Oral care compositions.
AR095431A1 (en) FORMULATIONS OF FVIII RECOMBINANT
Win The Yati (Vol 09 No 104) 2012/11
UA90689U (en) Lactoverm, complex antiparasitic composition
ES2426017A2 (en) Microemulsion comprising collagenase and uses (Machine-translation by Google Translate, not legally binding)
NZ756883A (en) Adeno-associated virus factor viii vectors